Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
96 studies found for:    selumetinib OR AZD6244 | Studies received from 01/01/2005 to 12/12/2020
Show Display Options
Rank Status Study
1 Completed A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244
Condition: Healthy Volunteers
Interventions: Drug: AZD6244 Dosing Period 1;   Drug: AZD6244 Dosing Period 2;   Drug: AZD6244 Dosing Period 3;   Drug: AZD6244 Dosing Period 4
2 Completed To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Condition: Solid Tumours
Intervention: Drug: selumetinib (oral)
3 Terminated AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Drug: AZD6244 and sorafenib
4 Unknown  A Study of Selumetinib in Patients With Kaposi's Sarcoma
Condition: AIDS-related Kaposi's Sarcoma
Intervention: Drug: Selumetinib
5 Recruiting Intermittent Selumetinib for Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: Selumetinib
6 Active, not recruiting AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
Conditions: Tumor;   Cancer
Intervention: Drug: AZD6244
7 Recruiting MEK Inhibitor and Thoracic Radiotherapy Trial
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AZD6244
8 Completed Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
Condition: Melanoma
Interventions: Drug: AZD6244;   Drug: Temozolomide
9 Completed
Has Results
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
10 Completed
Has Results
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Condition: Colorectal Neoplasms
Intervention: Drug: MK-2206 + AZD6244
11 Recruiting A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Conditions: Triple-Negative Breast Cancer;   Squamous Cell Lung Cancer;   Non-squamous Cell Lung Cancer With KRAS Mutations;   Non-squamous Cell Lung Cancer With Wild-type KRAS
Interventions: Drug: AZD2014;   Drug: AZD6244
12 Completed Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
Condition: Healthy Volunteers Pharmacokinetic Study
Intervention: Drug: Selumetinib
13 Completed To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Condition: Solid Tumours
Interventions: Drug: selumetinib;   Drug: rifampicin
14 Completed Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
Condition: Solid Tumours
Intervention: Drug: [C14] selumetinib (oral)
15 Completed Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
Condition: Colorectal Cancer
Interventions: Drug: AZD6244;   Drug: Irinotecan
16 Completed AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
Condition: Non-small Cell Lung Cancer
Interventions: Drug: AZD6244;   Drug: Pemetrexed
17 Completed
Has Results
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
Conditions: Neoplasms,;   Metastatic Cancer,;   Non-Small Cell Lung Cancer;   Advanced Solid Malignancies
Intervention: Drug: AZD6244
18 Terminated
Has Results
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
Condition: Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Selumetinib
19 Completed Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: AZD6244
20 Completed Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Condition: Breast Cancer
Interventions: Drug: fulvestrant;   Drug: selumetinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.